Abstracts tagged "Adverse events"

Abstract Number: 1865 • 2013 ACR/ARHP Annual Meeting
Complement Activation and Anaphylatoxin Generation In Response To Staphylococcal Protein A Exposure: Ex Vivo and In Vivo Human Studies
Edward Bernton¹, Antonio Polley², Susan Zondlo², Lynne Mitchell³ and Dennis Hourcade³, ¹Protalex Inc., Summit, NJ, ²QPS Holdings LLC, Newark, DE, ³Division of Rheumatology, Washington University School of Medicine, St. Louis, MO
Background/Purpose: PRTX-100, a highly-purified GMP staphylococcal protein A (SpA), is currently in clinical trials treating patients with active rheumatoid arthritis (RA). It has been reported…
Abstract Number: 1812 • 2013 ACR/ARHP Annual Meeting
Adverse Events In Connective Tissue Disease-Associated Pulmonary Arterial Hypertension Compared To Idiopathic Pulmonary Arterial Hypertension
Rennie L. Rhee¹, Nicole B. Gabler², Amy Praestgaard², Peter A Merkel³ and Steven M. Kawut⁴, ¹Rheumatology, University of Pennsylvania, Philadelphia, PA, ²Department of Biostatistics and Epidemiology, University of Pennsylvania, Philadelphia, PA, ³Division of Rheumatology, University of Pennsylvania and VA Medical Center, Philadelphia, PA, ⁴Division of Pulmonary, Allergy, and Critical Care, University of Pennsylvania, Philadelphia, PA
Background/Purpose: Whether the risk of treatment-related adverse events (AEs) in patients with pulmonary arterial hypertension (PAH) differs based on diagnosis, either connective tissue disease (CTD-PAH)…
Abstract Number: 1606 • 2013 ACR/ARHP Annual Meeting
Overview Of The Safety Of Epratuzumab In Systemic Lupus Erythematosus
Daniel J. Wallace¹, Josep Ordi-Ros², C. Michael Neuwelt³, Kenneth Kalunian⁴, Michelle A. Petri⁵, Slawomir Jeka⁶, Ronald F. van Vollenhoven⁷, Brian Kilgallen⁸, Sabine Bongardt⁹, Caroline Gordon¹⁰ and Vibeke Strand¹¹, ¹Cedars-Sinai Medical Center, Los Angeles, CA, ²Internal Medicine, Vall De Hebron General Hospt, Barcelona, Spain, ³East Bay Rheumatology Research Institute, San Leandro, CA, ⁴UCSD School of Medicine, La Jolla, CA, ⁵Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ⁶2nd University Hospital in Bydgoszcz Medical College of Nicolaus Copernicus University, Bydgoszcz, Poland, ⁷Clinical Trials Unit Department of Rheumatology, The Karolinska Institute, Stockholm, Sweden, ⁸UCB Pharma, Raleigh, NC, ⁹UCB Pharma, Brussels, Belgium, ¹⁰Rheumatology Research Group (East Wing), School of Immunity and Infection, University of Birmingham, Birmingham, United Kingdom, ¹¹Adjunct, Division of Immunology / Rheumatology, Stanford University, Palo Alto, CA
Background/Purpose: The efficacy and safety of epratuzumab, a monoclonal antibody targeting CD22, has been evaluated in patients with moderate-to-severe systemic lupus erythematosus (SLE). A pooled…
Abstract Number: 1462 • 2013 ACR/ARHP Annual Meeting
Unmasking The Tolerability Of Methotrexate In Patients With Rheumatoid and Psoriatic Arthritis: A Retrospective Review Of Discontinuation From a Large UK Cohort
Andra Negoescu¹, Elena Nikiphorou², Anshuman P. Malaviya³, Andrew Badcock³, John D. Fitzpatrick^3,4, Calum T. Goudie^3,4 and Andrew J. Ostor³, ¹Rheumatology, Rheumatology Research Unit, Addenbrooke's Hospital, Cambridge, United Kingdom, ²Rheumatology, Addenbrooke's Hospital, Cambridge, United Kingdom, ³Rheumatology Research Unit, Addenbrooke's Hospital, Cambridge, United Kingdom, ⁴University of Cambridge Medical School, Cambridge, United Kingdom
Background/Purpose: Due to its efficacy and perceived safety, methotrexate (MTX) has become the foundation disease-modifying drug for rheumatoid (RA) and psoriatic arthritis (PsA) however…
Abstract Number: 1038 • 2013 ACR/ARHP Annual Meeting
Impact Of Biological Treatment On Overall Mortality and On Incidence Of Second Cancers In Arthritis Patients – A Follow-Up Study From The Danish Danbio Registry
Lene Dreyer¹, Lene Mellemkjær², Inger Marie Jensen Hansen³ and Merete Lund Hetland⁴, ¹Internal Medicine - Rheumatology Section, Copenhagen University Hospital at Gentofte, Copenhagen, Denmark, ²Danish Cancer Society Research Center, Copenhagen, Denmark, ³Department of Reumatology, OUH Svendborg Hospital, Svendborg, Denmark, ⁴Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, The Danish Rheumatologic Database (DANBIO), Glostrup Hospital., Copenhagen, Denmark
Background/Purpose: It is largely unknown whether it is safe to treat arthritis patients with a previous malignancy with biologics. Only a few studies have address…
Abstract Number: 1041 • 2013 ACR/ARHP Annual Meeting
Non-Differential Reporting Of Myocardial Infarction To a National Observational Drug Safety Study Using Linked Data: Linkage Of The British Society For Rheumatology Biologics Register For Rheumatoid Arthritis and The Myocardial Ischaemia National Audit Project
Audrey SL Low¹, Deborah P. Symmons^2,3, Mark Lunt², Louise K. Mercer², Christopher Gale^4,5, Kath Watson⁶, British Society for Rheumatology Biologics Registers (BSRBR) Control Centre Consortium¹, William G. Dixon⁷, Kimme L. Hyrich⁸ and On behalf of the BSRBR⁹, ¹Arthritis Research UK Epidemiology Unit, The University of Manchester, Manchester, United Kingdom, ²Arthritis Research UK Centre for Epidemiology, University of Manchester, Manchester, United Kingdom, ³Arthritis Research UK Epidemiology Unit, University of Manchester, Manchester, United Kingdom, ⁴Division of Epidemiology, Centre for Epidemiology and Biostatistics, University of Leeds, Leeds, United Kingdom, ⁵Department of Cardiology,York Teaching Hospital NHS Foundation Trust, York, United Kingdom, ⁶Arthritis Research UK Epidemiology Unit, Arthritis Research UK Epidemiology Unit, The University of Manchester, Manchester, United Kingdom, ⁷The University of Manchester, Manchester, United Kingdom, ⁸Arthritis Research UK Epidemiology Unit, Manchester Academic Health Sciences Centre, Institute of Inflammation and Repair, The University of Manchester, Manchester, United Kingdom, ⁹British Society for Rheumatology, London, United Kingdom
Background/Purpose: The BSRBR-RA was established to compare the long term safety of anti tumour necrosis factor (TNFi) drugs with non-biologic drugs (nbDMARD) in subjects with…
Abstract Number: 1007 • 2013 ACR/ARHP Annual Meeting
Dose Of Corticosteroid, Risk Of Adverse Events and Healthcare Resource Utilization In Systemic Lupus Erythematosus
Wei-Shi Yeh¹, Shih-Yin Chen², Kathleen McCarty³, Qian Li², Yuan-Chi Lee² and Nathalie Franchimont³, ¹Biogen Idec, Cambridge, MA, ²United BioSource Corporation, Lexington, MA, ³Biogen Idec Inc., Weston, MA
Background/Purpose: Gluco-corticosteroids (GCs) are frequently used to treat autoimmune disease and their chronic use has long been known to cause adverse events (AEs). The purpose…
Abstract Number: 742 • 2013 ACR/ARHP Annual Meeting
Safety Of Remission Induction With Rituximab Versus Cyclosphosphamide In Patients 65 and Older With Severe ANCA-Associated Vasculitis
Eli Miloslavsky¹, Ulrich Specks², Peter A Merkel³, Philip Seo⁴, Robert F. Spiera⁵, Carol A. Langford⁶, Gary S. Hoffman⁷, Cees G.M. Kallenberg⁸, E. William St. Clair⁹, Nadia Tchao¹⁰, Linna Ding¹¹, David Ikle¹², Brett Jepson¹², Paul Brunetta¹³ and John H. Stone¹⁴, ¹Division of Rheumatology, Massachusetts General Hopsital, Boston, MA, ²Mayo Clinic, Rochester, MN, ³Division of Rheumatology, University of Pennsylvania and VA Medical Center, Philadelphia, PA, ⁴Rheumatology Division, Johns Hopkins Vasculitis Center, Johns Hopkins University, Baltimore, MD, ⁵Rheumatology, Hospital for Special Surgery, New York, NY, ⁶Center for Vasculitis Care and Research, Cleveland Clinic, Cleveland, OH, ⁷Center for Vasculitis Care and Research, Cleveland Clinic Foundation, Cleveland, OH, ⁸Rheumatology and Clinical Immunology, University Medical Center Groningen, Groningen, Netherlands, ⁹Medicine, Duke University Medical Center, Durham, NC, ¹⁰Immune Tolerance Network, Bethesda, MD, ¹¹NIAID, Bethesda, MD, ¹²Rho, Chapel Hill, NC, ¹³Biotherapeutics, Genentech, So San Francisco, CA, ¹⁴Rheumatology, Massachusetts General Hospital, Boston, MA
Background/Purpose: Retrospective studies have demonstrated that patients of advanced age with systemic vasculitis experience a higher mortality and adverse events than their younger counterparts. However,…
Abstract Number: 461 • 2013 ACR/ARHP Annual Meeting
Higher TNFi Dosing Is Not Associated With More Serious Infectious Events (SIE), Elevated AST/ALT Or WBC<1.5 In The US Corrona Database
Daniel Furst¹, Mei Liu², Jeffrey D. Greenberg³ and Joel M. Kremer⁴, ¹Rheumatology, David Geffen School of Medicine, UCLA, Los Angeles, CA, ²CORRONA, Inc, Southborough, MA, ³NYU Hospital for Joint Diseases, New York, NY, ⁴Albany Medical College and The Center for Rheumatology, Albany, NY
Higher TNFi Dosing Is Not Associated with More Serious Infectious Events (SIE), elevated AST/ALT or WBC 50 mg golim. q4wk for at least 3 months.Adverse…
Abstract Number: 260 • 2012 ACR/ARHP Annual Meeting
Adjudication of Reported Serious Adverse Joint Events in the Tanezumab Clinical Development Program
Marc C. Hochberg¹, Steven B. Abramson², David S. Hungerford³, Edward McCarthy⁴, Eric P. Vignon⁵, Michael D. Smith⁶, Leslie Tive⁷, Kenneth M. Verburg⁶ and Christine R. West⁸, ¹Department of Medicine, University of Maryland, Baltimore, MD, ²Dept of Rheumatology/Medicine, NYU Langone Medical Center, New York, NY, ³Department of Ortho Surgery, Johns Hopkins University, Baltimore, MD, ⁴Pathology, The Johns Hopkins University School of Medicine, Baltimore, MD, ⁵Rheumatology 2B, Centre Hospitalier, Pierre Benite, France, ⁶Pfizer, Inc., Groton, CT, ⁷Arthritis, Pfizer Inc, New York, NY, ⁸Clinical Sciences, Pfizer, Williamston, MI
Background/Purpose: Tanezumab (TNZ) has been shown to be efficacious for pain and function in patients with hip and knee osteoarthritis (OA). Unexpected reports of adverse…
Abstract Number: 2640 • 2012 ACR/ARHP Annual Meeting
Methotrexate Adverse Events in a Cohort of US Veterans with Rheumatoid Arthritis
Lisa A. Davis¹, Brooke Ivan Polk², Alyse D. Mann³, Gail S. Kerr⁴, Andreas M. Reimold⁵, Grant W. Cannon⁶, Ted R. Mikuls⁷ and Liron Caplan⁸, ¹Div of Rheumatology, Univ of Colorado School of Med, Aurora, CO, ²University of Colorado Medical School, Aurora, CO, ³Research, Denver VA Medical Center, Denver, CO, ⁴Rheumatology, Washington DC VAMC, Georgetown and Howard University, Washington, DC, ⁵Rheumatology, Dallas VA and University of Texas Southwestern, Dallas, TX, ⁶Division of Rheumatology, George E. Wahlen VA Medical Center, Salt Lake City, UT, ⁷Omaha VA Medical Center and University of Nebraska Medical Center, Omaha, NE, ⁸Div of Rheumatology, Denver VA and University of Colorado School of Medicine, Aurora, CO
Background/Purpose: Methotrexate (MTX) is the most commonly used medication for patients with rheumatoid arthritis (RA), however, the frequency of MTX adverse events (AE) has not…
Abstract Number: 2479 • 2012 ACR/ARHP Annual Meeting
Rheumatoid Arthritis Does Not Increase Risk of Short Term Total Knee Replacement (TKR) Adverse Events (AE)
Zachary J. LoVerde¹, Lisa A. Mandl², Beverly K. Johnson², Mark P. Figgie³, Friedrich Boettner⁴ and Susan M. Goodman², ¹New York Medical College, Valhalla, NY, ²Rheumatology, Hospital for Special Surgery, New York, NY, ³Orthopedics, Hospital for Special Surgery, New York, NY, ⁴Orthopaedics, Hospital for Special Surgery, New York, NY
Background/Purpose: TKR is commonly performed for rheumatoid arthritis (RA) and osteoarthritis (OA). Historically, RA patients were at higher risk of post-operative AEs. The purpose of…
Abstract Number: 2483 • 2012 ACR/ARHP Annual Meeting
Folic Acid Pathway Single Neucelotide Polymorphisms Associated with Methotrexate-Related Significant Adverse Events
Lisa A. Davis¹, Brooke Ivan Polk², Alyse D. Mann³, Roger K. Wolff⁴, Gail S. Kerr⁵, Andreas M. Reimold⁶, Grant W. Cannon⁷, Ted R. Mikuls⁸ and Liron Caplan⁹, ¹Div of Rheumatology, Univ of Colorado School of Med, Aurora, CO, ²University of Colorado Medical School, Aurora, CO, ³Research, Denver VA Medical Center, Denver, CO, ⁴University of Utah, Salt Lake City, UT, ⁵Rheumatology, Washington DC VAMC, Georgetown and Howard University, Washington, DC, ⁶Rheumatology, Dallas VA and University of Texas Southwestern, Dallas, TX, ⁷Division of Rheumatology, George E. Wahlen VA Medical Center, Salt Lake City, UT, ⁸Omaha VA Medical Center and University of Nebraska Medical Center, Omaha, NE, ⁹Div of Rheumatology, Denver VA and University of Colorado School of Medicine, Aurora, CO
Background/Purpose: Methotrexate (MTX) is the cornerstone medication in the treatment of rheumatoid arthritis (RA). While MTX has been associated with a number of adverse…
Abstract Number: 2169 • 2012 ACR/ARHP Annual Meeting
Short to Medium Term Safety of Glucocorticoid Therapy in Rheumatoid Arthritis: A Systematic Review and Dose-Response Analysis of Randomized Controlled Trials
Simon Tarp¹, Daniel Furst², John R. Kirwan³, Maarten Boers⁴, Henning Bliddal⁵, Thasia Woodworth⁶, Else Marie Bartels⁷, Bente Danneskiold-Samsoe⁵, Lars Erik Kristensen⁸, Steffen Thirstrup⁹, Mette Rasmussen⁹, Marian Kaldas¹⁰ and Robin Christensen¹, ¹Musculoskeletal Statistics Unit, The Parker Institute, Department of Rheumatology, Copenhagen University Hospital, Bispebjerg and Frederiksberg, Denmark, ²Div of Rheumatology, UCLA Medical School, Los Angeles, CA, ³Academic Rheumatology Unit, Bristol Royal Infirmary, Bristol, United Kingdom, ⁴Epidemiology & Biostatistics, VU University Medical Center, Amsterdam, Netherlands, ⁵Department of Rheumatology, The Parker Institute, Copenhagen University Hospital at Frederiksberg, Copenhagen F, Denmark, ⁶Leading Edge Clinical Research LLC, Florida, FL, ⁷Department of Rheumatology, The Parker Institute, Copenhagen University Hospital at Bispebjerg and Frederiksberg, Copenhagen F, Denmark, ⁸Rheumatology, Skåen University Hospital, Lund University, Lund, Sweden, ⁹Institute for Pharmacology and Pharmacotherapy, University of Copenhagen, Copenhagen, Denmark, ¹⁰David Geffen School of Medicine, University of California in Los Angeles, Los Angeles, CA
Background/Purpose: Concerns regarding Adverse Effects (AEs) often dominate decisions on applying Glucocorticoid (GC) therapy. Evidence of AEs is mainly based on observational data without proper…
Abstract Number: 2158 • 2012 ACR/ARHP Annual Meeting
Baseline Folate Related Biomarkers in Serum and erythrocytes Are Not Associated with Methotrexate Response and Adverse Events in Rheumatoid Arthritis
Maurits C.F.J. De Rotte¹, Saskia M.F. Pluijm², Maja Bulatovic³, Johanna M.W. Hazes⁴ and Robert De Jonge¹, ¹Clinical Chemistry, Erasmus Medical Center, Rotterdam, Netherlands, ²Public Health, Erasmus Medical center, Rotterdam, Netherlands, ³Department of Paediatric Immunology, University Medical Centre Utrecht, Netherlands, ⁴Rheumatology, Erasmus MC, Rotterdam, Netherlands
Background/Purpose: Methotrexate (MTX) is the most commonly used drug in rheumatoid arthritis (RA). 30% of patients fail to respond to the drug or suffer from…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].